What is The Hsieh Family Dynasty Trust’s role in FLGT share ownership?

The Hsieh Family Dynasty Trust holds 220,816 Fulgent Genetics shares reported as indirect ownership for Jian Xie. He serves on the trust’s investment committee and disclaims beneficial interest except for any pecuniary interest related to those securities.

Fulgent Genetics president sells shares for tax withholding

Fulgent Genetics, Inc. President and COO Jian Xie reported an open-market sale of 2,146 shares of common stock at a weighted-average price of $17.8855 per share on June 2, 2026.

Filing Impact

(Neutral)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Fulgent Genetics, Inc. President and COO Jian Xie reported an open-market sale of 2,146 shares of common stock at a weighted-average price of $17.8855 per share on June 2, 2026. According to the disclosure, the shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units granted on February 25, 2025.

Following the sale, Xie holds 367,605 shares of Fulgent Genetics common stock directly and an additional 220,816 shares indirectly through The Hsieh Family Dynasty Trust, where he serves on the investment committee and disclaims beneficial interest except for any pecuniary interest.

Insider Trade Summary

Net Seller: 2,146 shares

Net Sell 2 txns

Insider Xie Jian

Role President and COO

Sold 2,146 shs ($38K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,146	$17.8855	$38K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 367,605 shares (Direct); Common Stock — 220,816 shares (Indirect, By Trust)

Footnotes (3)

F1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.
F2. The shares were sold in multiple transactions at prices ranging from $17.63 to $18.10, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
F3. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.

Key Figures

Shares sold: 2,146 shares Weighted-average sale price: $17.8855 per share Direct holdings after transaction: 367,605 shares +3 more

6 metrics

Shares sold 2,146 shares Open-market sale on June 2, 2026

Weighted-average sale price $17.8855 per share Common stock sale on June 2, 2026

Direct holdings after transaction 367,605 shares Common stock directly owned following sale

Indirect holdings via trust 220,816 shares Held by The Hsieh Family Dynasty Trust

Sale price range $17.63–$18.10 per share Multiple transactions; range disclosed in footnote

Net buy/sell direction Net sell of 2,146 shares Form 4 transaction summary

Key Terms

restricted stock units, weighted-average sale price, tax withholding obligations, beneficial interest, +1 more

5 terms

restricted stock units financial

"the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted-average sale price financial

"prices ranging from $17.63 to $18.10, inclusive. The reported price reflects the weighted-average sale price."

tax withholding obligations financial

"shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units"

beneficial interest financial

"Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein."

Beneficial interest is the right to receive the economic benefits of an asset—such as dividends, interest, or sale proceeds—without necessarily holding legal title to it. For investors this matters because it determines who actually gains from an investment or trust, much like renting an apartment where the tenant enjoys living there and paying bills while the landlord holds the deed; understanding who has the beneficial interest affects income rights, voting influence, and risk exposure.

pecuniary interest financial

"Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did FLGT President Jian Xie report?

Jian Xie reported selling 2,146 shares of Fulgent Genetics common stock. The sale occurred on June 2, 2026 at a weighted-average price of $17.8855 per share to cover tax withholding obligations from recently vested restricted stock units.

Why did FLGT executive Jian Xie sell 2,146 shares of stock?

The shares were sold to satisfy tax withholding obligations from the vesting of restricted stock units granted on February 25, 2025. This type of sale is compensation-related and linked to equity awards rather than a discretionary open-market liquidation.

How many FLGT shares does Jian Xie own after this Form 4 filing?

After the reported sale, Jian Xie holds 367,605 shares of Fulgent Genetics common stock directly. He also has indirect ownership of 220,816 shares through The Hsieh Family Dynasty Trust, where he serves on the investment committee with limited beneficial interest.

At what price did FLGT’s Jian Xie sell his shares on June 2, 2026?

The 2,146 shares were sold in multiple trades between $17.63 and $18.10 per share. The reported weighted-average sale price was $17.8855, reflecting all transaction prices within that disclosed range for this tax-related sale event.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/03/2026 - 05:29 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xie Jian

(Last)

(First)

(Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE

CALIFORNIA

91731

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/02/2026		S		2,146⁽¹⁾	D	$17.8855⁽²⁾	367,605	D
Common Stock								220,816	I	By Trust⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.

2. The shares were sold in multiple transactions at prices ranging from $17.63 to $18.10, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

3. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.

	/s/ Paul Kim as Attorney-in-Fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR